NovaBay Total Debt To Capitalization from 2010 to 2024

NBY Stock  USD 0.59  0.02  3.28%   
NovaBay Pharmaceuticals Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2024. During the period from 2010 to 2024, NovaBay Pharmaceuticals Total Debt To Capitalization regression line of annual values had significance of  0.07 and arithmetic mean of  0.10. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.32996361
Current Value
0.35
Quarterly Volatility
0.51342433
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of NovaBay Pharmaceuticals over the last few years. It is NovaBay Pharmaceuticals' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

NovaBay Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.10
Coefficient Of Variation491.40
Mean Deviation0.43
Median0.04
Standard Deviation0.51
Sample Variance0.26
Range1.2651
R-Value0.49
Mean Square Error0.22
R-Squared0.24
Significance0.07
Slope0.06
Total Sum of Squares3.69

NovaBay Total Debt To Capitalization History

2024 0.35
2023 0.33
2022 0.0412
2021 0.0291
2020 0.0327
2016 0.78

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.33  0.35 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.